Skip to content
Open access

Anti-CD40L prevents meningeal B cell aggregates and mitigates progressive autoimmune encephalomyelitis.

Sep 2026 · Brain : a journal of neurology · 0 citations
Medicine

TL;DR

Anti-CD40L treatment may be an effective intervention to mitigate progressive immunopathology associated with meningeal TLS, and modulates and likely silences other CD40-dependent antigen-presenting cells in the CNS, including myeloid cells and astrocyte subsets.

Abstract

Compartmentalized inflammation within the CNS is considered to drive progressive immunopathology in multiple sclerosis (MS) independently of relapses. Meningeal tertiary lymphoid structures (TLS) represent an immune niche associated with histological signs of immunopathology, including demyelination in the adjacent CNS parenchyma. Here, we show that the opticospinal encephalomyelitis (OSE) mouse model, in which meningeal TLS develop spontaneously based on the interaction of myelin oligodendrocyte glycoprotein (MOG)-specific T cell receptor (TCR) transgenic T cells with MOG B cell receptor (BCR) transgenic B cells, recapitulates the dynamics and the histological features of meningeal TLS observed in human MS. Based on scRNAseq datasets of meningeal TLS from OSE mice, the CD40L-CD40 pathway is highly active in the T cell-B cell interaction in this niche. Accordingly, a monoclonal antibody to CD40L, applied systemically, abrogates the T-B interaction in the systemic compartment and even more so in the meningeal compartment. This leads to near-complete clearance of meningeal TLS, concomitant with clinical improvement of the progressive disease phase of OSE mice. In contrast, systemic B cell depletion with a monoclonal antibody to CD20 does not improve signs of progressive disease in the OSE model. Treatment with anti-CD40L is more effective in disrupting T-B interaction, the more the T-B interaction relies on the CD40L-CD40 pathway, and thus leads to a "semi-selective" targeting of meningeal TLS. In addition, not only B cells but the entire antigen-presenting compartment in the CNS is remodeled in the absence of CD40 engagement. Since these effects persist even after withdrawal of anti-CD40L treatment, no rebound episodes or resumption of progression are observed. In conclusion, anti-CD40L treatment may be an effective intervention to mitigate progressive immunopathology associated with meningeal TLS. Beyond B cells, anti-CD40L treatment also modulates and likely silences other CD40-dependent antigen-presenting cells in the CNS, including myeloid cells and astrocyte subsets.

Read PDF

Similar papers

Open access Sep 2026

Fibronectin inhibition restores myelination in endothelial TNFR2-dependent nonremitting experimental autoimmune encephalomyelitis.

Therapeutically, systemic fibronectin inhibition restored regeneration and clinical remission, as well as prevented OPC accumulation at lesions, providing strong preclinical evidence for fibronectin-targeting therapies in MS and other demyelinating disorders.

Aikaterini Nanou, Konstantinos Apostolou-Karampelis, V. Triantafyllidou et al. · 0 citations
Open access Sep 2026

Genetic Disruption at the CIP2A Locus Modulates T Cell Responses and Attenuates Experimental Autoimmune Encephalomyelitis

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) driven by pathogenic T cell-mediated inflammation. Fingolimod (FTY720), an approved therapy for MS, is an established activator of protein phosphatase 2A (PP2A). However the contribution of PP2A in autoimmune neuroinflammation r...

Mohd Moin Khan, I. Starskaia, Emilie Rydgren et al. · 0 citations
Sep 2026

Early molecular changes in the subfornical organ during experimental autoimmune encephalomyelitis.

Experimental autoimmune encephalomyelitis (EAE) is a commonly used animal model of multiple sclerosis that allows the investigation of early immune-neural interactions that may precede clinical symptoms. The subfornical organ (SFO), a sensory circumventricular structure devoid of a blood-brain barrier, is anatomically...

Jing-Jing Zhou, Li-Xia Zhou, Kai-Yue Song et al. · 0 citations
Review Open access Aug 2026

Memory CD4+ T cells in chronic uveitis: pathogenicity, mechanisms, and therapeutic implications

Chronic non-infectious uveitis (NIU) is a vision-threatening inflammatory disease in which relapses often occur despite corticosteroids, conventional immunosuppression, and biologic therapy. A growing body of experimental and human evidence indicates that disease persistence is not explained solely by transient effecto...

Maryam Shayan, Binapani Mahaling, Yi-He Chen · 0 citations
Review Sep 2026

Regulatory T cells as drivers of CNS remyelination: neuro-immune cross-talk and comparative insights from mammalian and zebrafish models.

The goal of this review is to demonstrate how Tregs can promote regeneration by balancing a variety of underlying molecular and cellular processes, and to draw comparisons between the mechanisms used by regeneration-competent and non-competent species.

Debasmita Baidya, Tandra Sarkar, B. Ray et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.